Fresenius Medical Care Confirms Positive Outlook for 2010

Shareholders Approve 13th Consecutive Annual Dividend Increase

(PresseBox) ( Bad Homburg, )
Fresenius Medical Care's Chief Executive Officer, Dr. Ben Lipps, continues to see attractive growth opportunities, confirming the company's positive outlook for the 2010 financial year at the annual general meeting in Frankfurt today. Lipps: "The 2009 fiscal year was another very successful one for Fresenius Medical Care. Once again, we were able to demonstrate that Fresenius Medical Care's business model is robust and sustainable. We had a very good start into 2010. We are clearly on track to meet our targets for the full year and achieve another record year." For 2010, Fresenius Medical Care expects more than $12 billion in revenue and net income1 between $950 million and $980 million.

Lipps also expects continued sustainable growth driven by an annual 5% to 6% increase in patients requiring dialysis treatment worldwide. Furthermore, Fresenius Medical Care will pursue strategic opportunities to consolidate its leading market positions. Key drivers of these opportunities include: increasing market share through a superior product portfolio, a strong commitment to quality, expanding the clinic network, a focus on integrated care and rolling out additional dialysis services.

Lipps also pointed out a significant increase in its number of employees. The addition of 3,322 people, an increase of 5.0% to a total of approximately 68,000 employees worldwide, was attributed primarily to strong organic growth of the dialysis care business in every region. Selected acquisitions also contributed to this growth. The number of employees is expected to rise again in 2010.

During the annual general meeting, the shareholders approved the 13th consecutive dividend increase with a large majority of 99.02%. The dividend will increase to €0.61 from €0.58 per ordinary share and to €0.63 from €0.60 per preference share.

With a further majority of 96.80%, shareholders also approved cancellation of the existing authorized capital along with the creation of new authorized capitals identical to those expiring in August 2010 and totaling up to €35 million and €25 million, respectively.

In addition, shareholders approved the actions taken and decisions made by the supervisory board and the management board with a majority of more than 99%.

At the annual general meeting, 74.36% of the subscribed capital was represented. Only ordinaryshare holders were entitled to vote.

This release contains forwardlooking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forwardlooking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forwardlooking statements in this release.
The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to service@pressebox.de.